I like to keep an eye on any competitors in the Covid-19 space. Here’s one I wasn’t aware of.
https://scienceblog.com/518240/stem-cell-trial-tests-treatment-for-often-fatal-covid-19-lung-damage/
It’s a phase 2 double blind clinical trial, randomised 1:1 with placebo, of bone marrow derived MSC’s targeting Covid-19 ARDs. Currently underway in California at one site with 5 more to come, 28/120 currently enrolled.
Interestingly also funded by the NIH and two other organisations.
To me it seems to be covering similar ground to MSB’s trial, but one phase behind.
The article (published yesterday) references MSC’s for GVHD and Crohns, and includes discussion of mortality rates.
As a point of comparison, imo it’s a very interesting read.
(Patent discussions to follow?)
Herro. Apologies if already posted.
Cell Therapy News/Articles, page-6222
-
- There are more pages in this discussion • 11,627 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |